Orakl raises $34m to test cancer drugs against patient biology
Orakl Oncology combines patient-derived tumour models, clinical information and AI to study how cancer treatments perform.

A digital model becomes more useful when it stays connected to real biology. Orakl Oncology is building that link for cancer drug development.
What happened
Orakl raised a $34m Series A, co-led by Norrsken VC and Singular, bringing total funding to $50m. It combines patient-derived tumour samples grown in the laboratory with clinical information and AI. The financing will expand its datasets, cancer coverage and teams in the US and UK.
Why it matters
Drug developers need to decide which treatments to advance and which patients to study. Laboratory models linked to patient information can help them investigate those questions earlier in development.
The bigger picture
The company’s assets extend beyond its algorithms. Generating biological data and maintaining hospital relationships are part of building an experimental platform that other researchers can use.
